StreetInsider.com News Articles

Kura Oncology reports positive long-term cancer drug trial data

Thu, 11 Jun 2026 08:03:16 -0400

Kura Oncology Inc. (NASDAQ: KURA) and Kyowa Kirin Co. Ltd. (TSE: 4151) reported long-term results from their Phase 1/2 KOMET-007 trial testing ziftomenib combined with intensive chemotherapy in newly diagnosed acute myeloid leukemia patients.

The single-arm trial showed a 12-month overall survival rate of 94% among NPM1-mutant AML patients and 71% among KMT2A-rearranged AML patients. The companies reported 96% composite complete remission rates in NPM1-mutant AML patients and 90% in KMT2A-rearranged AML patients.

Median overall survival was not reached in either patient population, with median follow-up of 17.6 months for NPM1-mutant patients and 11.0 months for KMT2A-rearranged patients. The trial included 49

Kura Oncology reports positive long-term cancer drug trial data

Thu, 11 Jun 2026 08:03:16 -0400

Kura Oncology reports positive long-term cancer drug trial data

Thu, 11 Jun 2026 08:03:16 -0400

Kura Oncology reports positive long-term cancer drug trial data

Thu, 11 Jun 2026 08:03:16 -0400

Kura Oncology reports positive long-term cancer drug trial data

Thu, 11 Jun 2026 08:03:16 -0400

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Thu, 11 Jun 2026 08:02:00 -0400

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –

– 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML –

– High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing –

– Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively –

– 12-month survival rate, remission rates, MRD negativity, durability of CR and tolerability compare

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Thu, 11 Jun 2026 08:02:00 -0400

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –

– 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML –

– High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing –

– Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively –

– 12-month survival rate, remission rates, MRD negativity, durability of CR and tolerability compare

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Thu, 11 Jun 2026 08:02:00 -0400

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –

– 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML –

– High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing –

– Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively –

– 12-month survival rate, remission rates, MRD negativity, durability of CR and tolerability compare

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Thu, 11 Jun 2026 08:02:00 -0400

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –

– 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML –

– High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing –

– Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively –

– 12-month survival rate, remission rates, MRD negativity, durability of CR and tolerability compare

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Thu, 11 Jun 2026 08:02:00 -0400

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –

– 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML –

– High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing –

– Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively –

– 12-month survival rate, remission rates, MRD negativity, durability of CR and tolerability compare

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Thu, 11 Jun 2026 08:02:00 -0400

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –

– 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML –

– High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing –

– Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively –

– 12-month survival rate, remission rates, MRD negativity, durability of CR and tolerability compare

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Thu, 11 Jun 2026 08:02:00 -0400

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –

– 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML –

– High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing –

– Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively –

– 12-month survival rate, remission rates, MRD negativity, durability of CR and tolerability compare

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Thu, 11 Jun 2026 08:02:00 -0400

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –

– 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML –

– High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing –

– Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively –

– 12-month survival rate, remission rates, MRD negativity, durability of CR and tolerability compare

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Thu, 11 Jun 2026 08:02:00 -0400

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –

– 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML –

– High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing –

– Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively –

– 12-month survival rate, remission rates, MRD negativity, durability of CR and tolerability compare

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Thu, 11 Jun 2026 08:02:00 -0400

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –

– 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML –

– High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing –

– Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively –

– 12-month survival rate, remission rates, MRD negativity, durability of CR and tolerability compare

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Thu, 11 Jun 2026 08:02:00 -0400

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –

– 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML –

– High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing –

– Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively –

– 12-month survival rate, remission rates, MRD negativity, durability of CR and tolerability compare

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Thu, 11 Jun 2026 08:02:00 -0400

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –

– 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML –

– High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing –

– Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively –

– 12-month survival rate, remission rates, MRD negativity, durability of CR and tolerability compare

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Thu, 11 Jun 2026 08:02:00 -0400

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –

– 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML –

– High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing –

– Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively –

– 12-month survival rate, remission rates, MRD negativity, durability of CR and tolerability compare

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Thu, 11 Jun 2026 08:02:00 -0400

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –

– 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML –

– High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing –

– Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively –

– 12-month survival rate, remission rates, MRD negativity, durability of CR and tolerability compare

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Thu, 11 Jun 2026 08:02:00 -0400

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –

– 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML –

– High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing –

– Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively –

– 12-month survival rate, remission rates, MRD negativity, durability of CR and tolerability compare

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Thu, 11 Jun 2026 08:02:00 -0400

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –

– 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML –

– High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing –

– Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively –

– 12-month survival rate, remission rates, MRD negativity, durability of CR and tolerability compare

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Thu, 11 Jun 2026 08:02:00 -0400

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –

– 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML –

– High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing –

– Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively –

– 12-month survival rate, remission rates, MRD negativity, durability of CR and tolerability compare

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Thu, 11 Jun 2026 08:02:00 -0400

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –

– 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML –

– High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing –

– Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively –

– 12-month survival rate, remission rates, MRD negativity, durability of CR and tolerability compare

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Thu, 11 Jun 2026 08:02:00 -0400

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –

– 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML –

– High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing –

– Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively –

– 12-month survival rate, remission rates, MRD negativity, durability of CR and tolerability compare

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Thu, 11 Jun 2026 08:02:00 -0400

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –

– 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML –

– High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing –

– Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively –

– 12-month survival rate, remission rates, MRD negativity, durability of CR and tolerability compare